Quantcast
Last updated on April 19, 2014 at 21:20 EDT

Latest Bisphosphonates Stories

2012-03-09 13:25:00

According to court documents, on February 27th, 2012, a jury trial began in the Superior Court for Atlantic County, New Jersey in In re: Fosamax Litigation (No. 282). Plaintiffs allege that their Fosamax use caused them to develop osteonecrosis of the jaw (ONJ). Fosamax, manufactured by Merck, is a drug approved by the FDA in 1995 to treat post-menopausal osteoporosis and Paget's disease of bone. ONJ is a rare bone disease that can cause the patient's jaw bone to deteriorate and die. The...

2012-02-24 08:00:00

The US Drug Watchdog says, "It sounds counterintuitive to think a drug like the osteoporosis drug called Fosamax could be a contributing factor in a incredibly painful, out of the blue femur break, but that is exactly what we are saying. We need to identify every woman in the United States, who had been using, any type of osteoporosis drug, or the osteoporosis drug called Fosamax for at least five years, and then for some unexplained reason, they suffered a broken femur, thighbone or what is...

2012-02-23 09:30:00

NEW YORK, Feb. 23, 2012 /PRNewswire/ -- Doctors and other healthcare professionals have grown increasingly concerned about the regulation paradigm the Food & Drug Administration is taking with regard to Fosamax - a widely used osteoporosis drug, as evidence of its link to abnormal bone fractures. The FDA has so far resisted adding labeling requirements to Fosamax's packaging that would warn against prolonged use. Such labels are necessary in light of the dangers long-term use of the...

2012-02-21 04:45:00

Attorneys Andres Alonso and David Krangle Announce that Alonso Krangle LLP has Filed Suit on Behalf of a Wisconsin Woman who was Diagnosed with a Right Femur Fracture after Using the Bisphosphonate, Fosamax, for over Five Years Melville, NY (PRWEB) February 20, 2012 The law firm Alonso Krangle LLP, a national law firm focused on fighting for the rights of victims due to drug side effects, announce their firm has filed a Fosamax lawsuit on behalf of Judy Kinning, a resident of Wisconsin,...

2012-02-14 15:00:00

The Rottenstein Law Group, which represents clients with claims stemming from the severe side effects of the drug Fosamax, is cautiously optimistic about the possibility that a new process will improve bone growth. New York, NY (PRWEB) February 14, 2012 According to a press release from the University of California, “[a] research team led by UC Davis Health System scientists has developed a novel technique to enhance bone growth by using a molecule which, when injected into the...

2012-02-07 21:15:00

According to court documents, on Jan. 31st, 2012 Susan Lange, a Washington County woman, on behalf of Vera Lange, filed the lawsuit No.3:2012cv00090 in Southern District Court, Illinois. Susan Lange accuses Merck Sharp & Dohme, Corp., the company manufacturing Fosamax, for allegedly making exaggerated claims about its benefits; Lange alleges Fosamax weakened the bones and increased the risk of injury. Fosamax is a drug developed to treat osteoporosis and other bone-related diseases. In...

2012-02-07 08:00:00

The US Drug Watchdog says, "The Foamax mess involving women taking an osteoporosis drug, and then getting a out of the blue femur break, is so counterintuitive, we don't think most middle aged, or older women would consider it a possibility. It is for this reason we want family members of women, who suffered an out of the blue femur break, to ask if their loved one was using the osteoporosis drug called Fosamax." The group says, "In the instance of Fosamax, we are talking about women, whose...

2012-02-06 03:38:00

ALBANY, New York, February 6, 2012 /PRNewswire/ -- In the news release, "Global Osteoporosis Market is Expected to Attain a Market Size of USD 6.8 billion in 2015, China Osteoporosis Market Will be Worth USD 2.5 Billion in 2015" issued on 31 Jan 2012 11:30 GMT, by Transparency Market Research over PR Newswire, we are advised by a representative of the company that in the headline "Market Size of USD 6.8 billion" has been changed to "Market Size of USD 11.4 billion"....

2012-01-31 05:30:00

ALBANY, New York, January 31, 2012 /PRNewswire/ -- According to a new report published by Transparency Market Research ( http://www.transparencymarketresearch.com) "Osteoporosis Drug Market- Global and China market analysis, size, trends and forecast (2010-2015) [http://www.transparencymarketresearch.com/osteoporosis-drug-market.html ]" Global Osteoporosis Market is estimated to be USD 7.3 billion in 2010 and expected to reach USD 11.4 billion in 2015 at a CAGR of 9.2% over the...

2012-01-27 10:32:21

Findings could lead to a screening test Researchers at the Columbia University College of Dental Medicine have identified a genetic variation that raises the risk of developing serious necrotic jaw bone lesions in patients who take bisphosphonates, a common class of osteoclastic inhibitors. The discovery paves the way for a genetic screening test to determine who can safely take these drugs. The study appears in the online version of the journal The Oncologist. Oral bisphosphonates are...